Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1972 Jan;51(1):39–44. doi: 10.1172/JCI106794

Immunization of Humans with Polyribophosphate, the Capsular Antigen of Hemophilus influenzae, Type b

Porter Anderson 1,2, Georges Peter 1,2, Richard B Johnston Jr 1,2, Leslie H Wetterlow 1,2, David H Smith 1,2
PMCID: PMC332926  PMID: 4536615

Abstract

In human volunteers, single injections of purified polyribophosphate elicited antibodies detectable by passive hemagglutination and by serum bactericidal and opsonizing activities against viable Hemophilus influenzae, type b. All three activities rose by 2 wk to maximal levels, at which they remained for at least 6 months. Doses of 1 μg elicited antibody responses in nearly all recipients; higher doses of the antigen, however, produced larger increases in titer. Booster doses of 1 μg given at 6 months did not further increase the antibody titers. A tuberculin-like response was often observed at the site of injections given intradermally.

Full text

PDF
39

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P., Johnston R. B., Jr, Smith D. H. Human serum activities against Hemophilus influenzae, type b. J Clin Invest. 1972 Jan;51(1):31–38. doi: 10.1172/JCI106793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Artenstein M. S., Gold R., Zimmerly J. G., Wyle F. A., Branche W. C., Jr, Harkins C. Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis. 1970 Apr;121(4):372–377. doi: 10.1093/infdis/121.4.372. [DOI] [PubMed] [Google Scholar]
  3. Artenstein M. S., Gold R., Zimmerly J. G., Wyle F. A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970 Feb 19;282(8):417–420. doi: 10.1056/NEJM197002192820803. [DOI] [PubMed] [Google Scholar]
  4. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  5. Paul W. E., Siskind G. W., Benacerraf B., Ovary Z. Secondary antibody responses in haptenic systems: cell population selection by antigen. J Immunol. 1967 Oct;99(4):760–770. [PubMed] [Google Scholar]
  6. ROSENBERG E., ZAMENHOF S. Further studies on polyribophosphate. J Biol Chem. 1961 Nov;236:2845–2849. [PubMed] [Google Scholar]
  7. Sell S. H. The clinical importance of Hemophilus influenzae infections in children. Pediatr Clin North Am. 1970 May;17(2):415–426. doi: 10.1016/s0031-3955(16)32419-1. [DOI] [PubMed] [Google Scholar]
  8. ZAMENHOF S., LEIDY G., FITZGERALD P. L., ALEXANDER H. E., CHARGAFF E. Polyribophosphate, the type-specific substance of Hemophilus influenzae, type b. J Biol Chem. 1953 Aug;203(2):695–704. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES